Patent ID: 11896615
Assignee: JUNO THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  C  G

Claim 5:
6. The method of claim 1, wherein inhibitor of IDO1 is administered at a time in which:
there is a decrease in tryptophan levels, an increase in kynurenine levels, or an increase in expression or activity of IDO1 in a biological sample from the subject compared to prior to the initiation of administration of the T cell therapy or compared to a preceding time point after the initiation of administration of the T cell therapy;
at a time before the number of cells of the T cell therapy detectable in the blood from the subject is decreased compared to in the subject at a preceding time point after the initiation of administration of the T cell therapy;
at a time before T cells exhibit manifestations of prolonged tryptophan starvation, exhaustion, reduction of effector function, expression of inhibitory receptors, or loss of proliferative capacity;
at a time before a peak or maximum level of the cells of the T cell therapy are detectable in the blood of the subject; or
the level of interferon-gamma (IFNγ) is increased in a biological sample from the subject compared to prior to the initiation of administration of the T cell therapy or compared to a preceding time point after the initiation of administration of the T cell therapy.